Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 101–200 of 1,015
Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling
Luo, M., Shang, L., Brooks, M. D., Jiagge, E., Zhu, Y., Buschhaus, J. M., Conley, S., Fath, M. A., Davis, A., Gheordunescu, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.006 · Cited by 358
Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy
Li, H., Kim, Y., Jung, H., Hyun, J. Y., & Shin, I. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00722c · Cited by 356
Wu, T., Liu, Y., Cao, Y., & Liu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202110364 · Cited by 356
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 351
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Chen, X., Duan, N., Zhang, C., & Zhang, W. (2016) · Journal of Cancer · doi:10.7150/jca.13332 · Cited by 347
Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy
Zamora, A., Vigueras, G., Rodríguez, V., Santana, M. D., & Ruiz, J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.010 · Cited by 345
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment
Chen, B., Dai, W., He, B., Zhang, H., Wang, X., Wang, Y., & Zhang, Q. (2017) · Theranostics · doi:10.7150/thno.16684 · Cited by 342
Aspartate is an endogenous metabolic limitation for tumour growth
Sullivan, L. B., Luengo, A., Danai, L. V., Bush, L. N., Diehl, F. F., Hosios, A. M., Lau, A. N., Elmiligy, S., Malstrom, S., Lewis, C. A., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0125-0 · Cited by 341
Fluegen, G., Avivar-Valderas, A., Wang, Y., Padgen, M. R., Williams, J. K., Nobre, A. R., Calvo, V., Cheung, J. F., Bravo-Cordero, J. J., Entenberg, D., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3465 · Cited by 336
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Cancer therapy in the necroptosis era
Su, Z., Yang, Z., Xie, L., DeWitt, J. P., & Chen, Y. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.8 · Cited by 333
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Lim, A. R., Rathmell, W. K., & Rathmell, J. C. (2020) · eLife · doi:10.7554/elife.55185 · Cited by 327
Advances in cobalt complexes as anticancer agents
Munteanu, C. R., & Suntharalingam, K. (2015) · Dalton Transactions · doi:10.1039/c5dt02101d · Cited by 330
Yang, G., Phua, S. Z. F., Lim, W. Q., Zhang, R., Feng, L., Liu, G., Wu, H., Bindra, A. K., Jana, D., Liu, Z., et al. (2019) · Advanced Materials · doi:10.1002/adma.201901513 · Cited by 333
Imaging tumour hypoxia with positron emission tomography
Fleming, I. N., Manavaki, R., Blower, P. J., West, C., Williams, K. J., Harris, A. L., Domarkas, J., Lord, S., Baldry, C., & Gilbert, F. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.610 · Cited by 330
Liu, J., Liu, Y., Bu, W., Bu, J., Sun, Y., Du, J., & Shi, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5042989 · Cited by 332
Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use
Pastorek, J., & Pastorekova, S. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.08.002 · Cited by 328
Cancer Metabolism: The Role of ROS in DNA Damage and Induction of Apoptosis in Cancer Cells
Zhao, Y., Ye, X., Xiong, Z., Ihsan, A., Ares, I., Martínez, M., Lopez-Torres, B., Martínez-Larrañaga, M.-R., Anadón, A., Wang, X., et al. (2023) · Metabolites · doi:10.3390/metabo13070796 · Cited by 323
Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy
Marengo, B., Nitti, M., Furfaro, A. L., Colla, R., Ciucis, C. D., Marinari, U. M., Pronzato, M. A., Traverso, N., & Domenicotti, C. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/6235641 · Cited by 319
Sultana, A., Zare, M., Thomas, V., Kumar, T. S. S., & Ramakrishna, S. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100134 · Cited by 315
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 317
Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT)
Dang, J., He, H., Chen, D., & Yin, L. (2017) · Biomaterials Science · doi:10.1039/c7bm00392g · Cited by 317
Tang, W., Dong, Z., Zhang, R., Yi, X., Yang, K., Jin, M., Yuan, C., Xiao, Z., Liu, Z., & Cheng, L. (2019) · ACS Nano · doi:10.1021/acsnano.8b05982 · Cited by 314
Park, J. E., Dutta, B., Tse, S. W., Gupta, N., Tan, C. F., Low, J. K., Yeoh, K. W., Kon, O. L., Tam, J. P., & Sze, S. K. (2019) · Oncogene · doi:10.1038/s41388-019-0782-x · Cited by 315
Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review
Thakkar, S., Sharma, D., Kalia, K., & Tekade, R. K. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.009 · Cited by 316
Koo, S., Park, O. K., Kim, J., Han, S. I., Yoo, T. Y., Lee, N., Kim, Y. G., Kim, H., Lim, C., Bae, J.-S., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c09171 · Cited by 307
The impact of hypoxia and its modification of the outcome of radiotherapy
Horsman, M. R., & Overgaard, J. (2016) · Journal of Radiation Research · doi:10.1093/jrr/rrw007 · Cited by 311
Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors
Liu, Y., Jiang, Y., Zhang, M., Tang, Z., He, M., & Bu, W. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00214 · Cited by 307
Bacteria‐Based Cancer Immunotherapy
Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 304
Recent Advances in Glucose‐Oxidase‐Based Nanocomposites for Tumor Therapy
Wang, M., Wang, D., Chen, Q., Li, C., Li, Z., & Lin, J. (2019) · Small · doi:10.1002/smll.201903895 · Cited by 302
Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L., Schuetze, S., Reed, D., Chawla, S. P., Riedel, R. F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30381-9 · Cited by 302
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Molecular and nanoengineering approaches towards activatable cancer immunotherapy
Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 302
EMT in cervical cancer: Its role in tumour progression and response to therapy
Qureshi, R., Arora, H., & Rizvi, M. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.09.021 · Cited by 301
Liang, R., Liu, L., He, H., Chen, Z., Han, Z., Luo, Z., Wu, Z., Zheng, M., Ma, Y., & Cai, L. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.051 · Cited by 300
Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond
Tam, S. Y., Wu, V. W. C., & Law, H. K. W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00486 · Cited by 298
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Development of Azo‐Based Fluorescent Probes to Detect Different Levels of Hypoxia
Piao, W., Tsuda, S., Tanaka, Y., Maeda, S., Liu, F., Takahashi, S., Kushida, Y., Komatsu, T., Ueno, T., Terai, T., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201305784 · Cited by 293
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
Oxygen and Pt(II) self-generating conjugate for synergistic photo-chemo therapy of hypoxic tumor
Xu, S., Zhu, X., Zhang, C., Huang, W., Zhou, Y., & Yan, D. (2018) · Nature Communications · doi:10.1038/s41467-018-04318-1 · Cited by 292
Fibroblast activation in cancer: when seed fertilizes soil
Kuzet, S.-E., & Gaggioli, C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2467-x · Cited by 290
Redox homeostasis: the linchpin in stem cell self-renewal and differentiation
Wang, K., Zhang, T., Dong, Q., Nice, E. C., Huang, C., & Wei, Y. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.50 · Cited by 288
Jiang, L., Bai, H., Liu, L., Lv, F., Ren, X., & Wang, S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905884 · Cited by 288
The Emerging Role of Multifunctional Theranostic Materials in Cancer Nanomedicine
Figueiredo, P., Bauleth-Ramos, T., Hirvonen, J., Sarmento, B., & Santos, H. A. (2018) · Handbook of Nanomaterials for Cancer Theranostics · doi:10.1016/b978-0-12-813339-2.00001-3 · Cited by 287
Strategies for enhancing cancer chemodynamic therapy performance
Jana, D., & Zhao, Y. (2022) · Exploration · doi:10.1002/exp.20210238 · Cited by 284
Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., Yang, J., Tang, J., Wang, J., Chen, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29681 · Cited by 286
“Hypoxia is common in HCC and impacts universally on all cells within tumors, including tumor cells and stromal cells.((3)) The influence of hypoxia on tumor cells has been widely studied; however, for tumorassociated macrophages (TAMs), which play a critical role”
BackgroundTargeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Fang, H., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 284
Carbonic Anhydrases: Role in pH Control and Cancer
Mboge, M., Mahon, B., McKenna, R., & Frost, S. (2018) · Metabolites · doi:10.3390/metabo8010019 · Cited by 281
Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
Joseph, J. P., Harishankar, M. K., Pillai, A. A., & Devi, A. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.03.004 · Cited by 282
Emerging Roles of Energy Metabolism in Ferroptosis Regulation of Tumor Cells
Yao, X., Li, W., Fang, D., Xiao, C., Wu, X., Li, M., & Luo, Z. (2021) · Advanced Science · doi:10.1002/advs.202100997 · Cited by 282
Shi, G., Monro, S., Hennigar, R., Colpitts, J., Fong, J., Kasimova, K., Yin, H., DeCoste, R., Spencer, C., Chamberlain, L., et al. (2015) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.04.012 · Cited by 279
Saito, Y., Chapple, R. H., Lin, A., Kitano, A., & Nakada, D. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.019 · Cited by 273
Tang, Y.-A., Chen, Y.-F., Bao, Y., Mahara, S., Yatim, S. M. J. M., Oguz, G., Lee, P. L., Feng, M., Cai, Y., Tan, E. Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801348115 · Cited by 277
Cheng, H., Zhang, S., Qi, J., Liang, X., & Yoon, J. (2021) · Advanced Materials · doi:10.1002/adma.202007290 · Cited by 276
Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Salem, A., Asselin, M.-C., Reymen, B., Jackson, A., Lambin, P., West, C. M. L., O’Connor, J. P. B., & Faivre-Finn, C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx160 · Cited by 266
Zhao, X., Long, S., Li, M., Cao, J., Li, Y., Guo, L., Sun, W., Du, J., Fan, J., & Peng, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11800 · Cited by 264
McDonald, P. C., Chia, S., Bedard, P. L., Chu, Q., Lyle, M., Tang, L., Singh, M., Zhang, Z., Supuran, C. T., Renouf, D. J., et al. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000691 · Cited by 256
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review
Kumari, R., Sunil, D., & Ningthoujam, R. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.041 · Cited by 263
Microenvironment and tumor cell plasticity: An easy way out
Taddei, M. L., Giannoni, E., Comito, G., & Chiarugi, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.042 · Cited by 264
Emerging Functions of Regulatory T Cells in Tissue Homeostasis
Sharma, A., & Rudra, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00883 · Cited by 262
Mierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 262
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 262
Cheng, L., Shen, S., Shi, S., Yi, Y., Wang, X., Song, G., Yang, K., Liu, G., Barnhart, T. E., Cai, W., et al. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201504810 · Cited by 261
Structural Simplification of Natural Products
Wang, S., Dong, G., & Sheng, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00504 · Cited by 254
Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258
Marie-Egyptienne, D. T., Lohse, I., & Hill, R. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.11.019 · Cited by 256
Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers
Buckley, A. M., Lynam-Lennon, N., O’Neill, H., & O’Sullivan, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0247-2 · Cited by 254
Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways
Morgan, M. A., & Lawrence, T. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3229 · Cited by 250
Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy
Ye, Y., Hu, Q., Chen, H., Liang, K., Yuan, Y., Xiang, Y., Ruan, H., Zhang, Z., Song, A., Zhang, H., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0045-8 · Cited by 250
Biomaterials tools to modulate the tumour microenvironment in immunotherapy
Chao, Y., & Liu, Z. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00004-6 · Cited by 245
Sun, Y., Zhao, D., Wang, G., Wang, Y., Cao, L., Sun, J., Jiang, Q., & He, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.004 · Cited by 250
Zhang, Q., Bai, X., Chen, W., Ma, T., Hu, Q., Liang, C., Xie, S., Chen, C., Hu, L., Xu, S., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt027 · Cited by 248
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
Ashton, T. M., Fokas, E., Kunz-Schughart, L. A., Folkes, L. K., Anbalagan, S., Huether, M., Kelly, C. J., Pirovano, G., Buffa, F. M., Hammond, E. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12308 · Cited by 247
Moriwaki, K., Bertin, J., Gough, P. J., Orlowski, G. M., & Chan, F. K. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.16 · Cited by 247
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
Emblem, K. E., Mouridsen, K., Bjornerud, A., Farrar, C. T., Jennings, D., Borra, R. J. H., Wen, P. Y., Ivy, P., Batchelor, T. T., Rosen, B. R., et al. (2013) · Nature Medicine · doi:10.1038/nm.3289 · Cited by 246
Cancer Cell Membrane‐Biomimetic Oxygen Nanocarrier for Breaking Hypoxia‐Induced Chemoresistance
Tian, H., Luo, Z., Liu, L., Zheng, M., Chen, Z., Ma, A., Liang, R., Han, Z., Lu, C., & Cai, L. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703197 · Cited by 243
Oxidative stress in inflammation‐based gastrointestinal tract diseases: Challenges and opportunities
Kim, Y. J., Kim, E., & Hahm, K. B. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07108.x · Cited by 242
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Phillips, R. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2920-7 · Cited by 238
Ye, S., Zhang, H., Cai, T., Liu, Y., Ni, J., He, J., Peng, J., Chen, Q., Mo, H., Jun‐Cui, et al. (2016) · The Journal of Pathology · doi:10.1002/path.4781 · Cited by 238
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 237
Hypoxia‐Targeted siRNA Delivery
Perche, F., Biswas, S., Wang, T., Zhu, L., & Torchilin, V. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308368 · Cited by 234
Liu, J., Cabral, H., & Mi, P. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115239 · Cited by 229
Wang, S., Zheng, H., Zhou, L., Cheng, F., Liu, Z., Zhang, H., & Zhang, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120314 · Cited by 232
Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy
Zhang, R., Feng, L., Dong, Z., Wang, L., Liang, C., Chen, J., Ma, Q., Zhang, R., Chen, Q., Wang, Y., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.004 · Cited by 234
Pan, W.-L., Tan, Y., Meng, W., Huang, N.-H., Zhao, Y.-B., Yu, Z.-Q., Huang, Z., Zhang, W.-H., Sun, B., & Chen, J.-X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121449 · Cited by 233
Stimuli-responsive ferroptosis for cancer therapy
Kang, N., Son, S., Min, S., Hong, H., Kim, C., An, J., Kim, J. S., & Kang, H. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00001j · Cited by 228
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Wang, Z., Liu, B., Sun, Q., Dong, S., Kuang, Y., Dong, Y., He, F., Gai, S., & Yang, P. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c01539 · Cited by 228
Development and MPI tracking of novel hypoxia-targeted theranostic exosomes
Jung, K. O., Jo, H., Yu, J. H., Gambhir, S. S., & Pratx, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.048 · Cited by 229
Meng, X., Zhang, J., Sun, Z., Zhou, L., Deng, G., Li, S., Li, W., Gong, P., & Cai, L. (2018) · Theranostics · doi:10.7150/thno.26607 · Cited by 230
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Hunter, F. W., Wouters, B. G., & Wilson, W. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.79 · Cited by 228
Self-citationCancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 226
Chang, S., Yim, S., & Park, H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228
Yong, Y., Zhang, C., Gu, Z., Du, J., Guo, Z., Dong, X., Xie, J., Zhang, G., Liu, X., & Zhao, Y. (2017) · ACS Nano · doi:10.1021/acsnano.7b03037 · Cited by 228
Epithelial to mesenchymal transition in head and neck squamous cell carcinoma
Smith, A., Teknos, T. N., & Pan, Q. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.10.009 · Cited by 226
Recent Advances of Light-Mediated Theranostics
Ai, X., Mu, J., & Xing, B. (2016) · Theranostics · doi:10.7150/thno.16088 · Cited by 226
Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids
Riffle, S., & Hegde, R. S. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0570-9 · Cited by 227
Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications
Uthaman, S., Huh, K. M., & Park, I.-K. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0132-z · Cited by 227
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.